Status:

TERMINATED

PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine

Lead Sponsor:

Pfizer

Conditions:

Neoplasms

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

To determine the overall safety of PF-00477736 when given in combination with gemcitabine, a chemotherapy agent, in patients with advanced solid tumors and determine the maximum dose of PF-00477736 th...

Detailed Description

The study was closed to enrollment as of 17 May 2010 due to business reasons. The patient on study continued treatment until 19 April 2011 when stopped for complete response. Premature closure was not...

Eligibility Criteria

Inclusion

  • Histological or cytopathological diagnosis of solid malignancy that is refractory to standard therapy or for which no curative therapy exists.
  • ECOG performance status 0 or 1.
  • Adequate blood cell counts, kidney function and liver function.

Exclusion

  • Prior treatment with gemcitabine.
  • Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.
  • NCI CTC Grade 2 or higher ARDS, non-infectious pneumonitis, or pulmonary fibrosis.
  • NCI CTC Grade 2 or higher cardiovascular toxicities with the exception of NCI CTC Grade 3 hypertension that is well controlled.
  • Known human immunodeficiency virus (HIV) seropositivity.
  • Concurrent treatment with anticoagulants or known coagulopathy

Key Trial Info

Start Date :

December 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2011

Estimated Enrollment :

43 Patients enrolled

Trial Details

Trial ID

NCT00437203

Start Date

December 1 2006

End Date

April 1 2011

Last Update

April 3 2012

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Pfizer Investigational Site

Los Angeles, California, United States, 90095-6984

2

Pfizer Investigational Site

Los Angeles, California, United States, 90095

3

Pfizer Investigational Site

Santa Monica, California, United States, 90403

4

Pfizer Investigational Site

Santa Monica, California, United States, 90404

PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine | DecenTrialz